Other Events ·
Collegium pays $17M to settle patent suit with Grünenthal and terminate license
COLLCollegium Pharmaceutical, Inc
Collegium Pharmaceutical has entered into a settlement agreement with Grünenthal GmbH to resolve all disputes, including ongoing patent infringement litigation regarding the authorized generic for Nucynta ER. As part of the deal, Collegium paid Grünenthal $17 million on October 15, 2026. The parties mutually agreed to terminate the Grünenthal License in its entirety and the Consent Agreement with respect to the Territory, effectively discharging all future royalty obligations under that license. Grünenthal assigned certain related patents to Collegium and filed a motion to dismiss the litigation. Collegium Pharmaceutical operates in the pharmaceutical industry, focusing on the development and commercialization of non-opioid pain management therapies.